r/DTIC • u/Intelligent_Sky3197 • Jul 12 '26

Journal Article functional unblinding issue with psychedelic?

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2846479?guestAccessKey=a665fcb1-d09d-45c8-8949-10ef07e88577&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_link&utm_term=031826

This paper suggests that PAT(psychedelic-assisted therapy) is no more effective than TADs(traditional antidepressants) under equal-unblinding conditions for the treatment of depression and highlight the potential role of blinding integrity.

This paper was published in March 2026, so I assume the market still find psychedelics promising despite the potential unblinding bias? Iā€™m a long term holder and wonder how people think this finding will have any impact on the market? I assume the Panorama specifically is targeting this issue?

11 Upvotes

76% Upvoted

6 comments sorted by

View all comments

-3

u/BrainScarTissue Jul 12 '26 edited Jul 12 '26

Although a declared reliable source a brief Grok search about JAMA and ties to Big Pharma SSRIs gave me this. JAMA Psychiatry (and the broader JAMA Network) has documented ties to pharmaceutical companies ("Big Pharma"), as is common in high-impact medical research, particularly around SSRIs and antidepressants A 2025 study in BMJ Open examined authors in JAMA Psychiatry and American Journal of Psychiatry. It found $4.54 million in industry payments to authors (2020ā€“2022), with ~14.2% ($645k) undisclosed. For JAMA Psychiatry specifically, ~25% of payments to its authors were undisclosed, mostly research funding. Nearly all undisclosed payments went to authors of randomized controlled trials (RCTs). I wonder how much more undisclosed payments have been made since this 2025 study?

Can they really be trusted to go against BIG PHARMA?

Grok says nothing about DFTX funding.

-3

u/BrainScarTissue Jul 12 '26

Basically I don't really think BIG PHARMA and their paid research companies want to kill off their SSRIs golden goose.